THE EFFICACY AND **SAFETY OF PNEUMATIC TRABECULOPLASTY: RESULTS OF A 6-MONTH, MULTICENTER STUDY**

Fogagnolo P (1), Rossetti L (2), Marraffa M (3), Rolando M (4), Ciancaglini M (5), Marchini G (3), Calabria G (4), Mastropasqua L (5), Orzalesi N (2)

(1) G.B. Bietti Foundation for the Study and Research in Ophthalmology, IRCCS, Rome, Italy
(2) Eye Clinic, San Paolo Hospital, University of Milan, Italy
(3) Eye Clinic, Department of Neurological and Vision Science, University of Verona, Italy
(4) Department of Ophthalmology, University of Genoa, Italy
(5) Ophthalmic Clinic, University of Chieti, Italy



FONDAZIONE G.B.BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA - ONLUS IRCCS - Istituto di Ricovero e Cura a Carattere Scientifico

CAL AND A PROPERTY

sostenuta dalla Fondazione Cassa di Risparmio di Roma

10.0 4



INTRODUCTION

Pneumatic trabeculoplasty (PNT) is a novel device for the treatment of OHN and POAG

Few clinical data are up-to-now available

PURPOSE

To evaluate the efficacy and safety of PNT in patients with OHT and POAG

METHODS

4 Italian academic sites
 63 patients
 Worse eye = PNT
 Fellow eyes = CONTROLS

INCLUSION CRITERIA

diagnosis of OHT or POAG
 IOP = 20 - 25 mmHg
 (treated & untreated - washout not required)

EXCLUSION CRITERIA

 mean defect < -12 dB
 past intraocular surgery or inflammation
 significant eye diseases
 myopia > 6 D

SCHEDULED VISITS

BASELINE (day -1)[©] PNT TREATMENT (day 0, day 7) SAFETY VISIT (day 1, day 8) **FOLLOW-UP VISITS** (month 1, 2, 3, 4, 5, 6)[©] [©] daytime IOP curve (8, 10 am, 2, 4 pm)

THE PROCEDURE

Tetracaine 0.5% The lids are gently spread by the physician using his fingers A sterile PNT ring is centered on the cornea Moderate downward pressure to facilitate the initial attachment of the ring Vacuum of 20 inches Hg is applied to the ring and to the eyes 60 seconds; rest of 5 minutes; 60 seconds Topical antibiotic + non steroid anti-inflammatory eyedrops (QID, 1/52)



PATIENTS' CHARACTERISTICS

P.P. C. Marken

Age at inclusion	mean ± SD (range)	66 ± 10 years (42-87)	
Race, n	Caucasian / Black	98% / 2%	
Male / Female, %		57% / 43%	
Iris, %	Pigmented / Not pigmented	74% / 26%	
Study discontinuations, n (%)		8 (13%)	
	ITTE STATE	STAR SAN	
WAS LOND		PNT eye	Not-PNT eye
OD/OS		60% / 40%	40% / 60%
POAG / OHT		40% / 60%	56% / 44%
Treatment, n	None	21%	17%
	Prostaglandin analogues	49%	25%
	Beta-blockers	35%	29%
	Others	3%	5%

RESULTS



Mean IOP decrease from baseline: 17.9% ± 19.1% $\textcircled{Rate of non-responders} (\leq 5\%)$: 23% - 32%Mean IOP decrease in responders: 23.0% ± 18.2% Significant decrease also in untreated eyes (except at day 180) Trend for better responses in PNT group using prostaglandin analogues compared to betablockers (22.8% ± 16.0% vs 11.0% ± 14.9%, P = 0.17)





SIDE EFFECTS	N (%)	DURATION , mean ± SD (range)	
Conjunctival hyperaemia	31 (49%)	12 ± 20 days (1; 90)	
Foreign body sensation	11 (17%)	10 ± 13 days (1; 45)	
Punctuate keratitis	8 (<mark>13%)</mark>	7 ± 0 days	
Blurred vision	7 (11%)	1 ± 2 hours (15 mins – 5 hours)	
Subconjunctival haemorrhage	5 (<mark>8%)</mark>	5 ± 6 days (1; 14)	
Burning	4 (6%)	6 ± 6 days (1; 14)	
Dry eye sensation	3 (5%)	10 ± 6 days (1; 14)	
Corneal abrasion	1 (2%)	7 days	
Corneal oedema	1 (2%)	7 days	
IOP increase to 40 mmHg	1 (2%)	1 day	
Photophobia	1 (2%)	1 day	

CONCLUSIONS

- SAFE (up to 6 months)
- EFFECTIVE
- UNEXPLAINED DECREASE IN FELLOW EYES
- HIGH RATE OF NON-RESPONDERS
- Many unresolved questions:
- ... mechanism of action? synergic to PG?
- ... repetitions: how often? are they effective?
- ... decrease in fellow eye?

"Oculus" by Andrea Mantegna (1431 – 1506) La Camera degli Sposi, Palazzo Ducale, Mantova – Italy

contact: fogagnolopaolo@googlemail.com

